Health Economic Outcomes of a Minimal Monitoring Approach to Providing HCV Therapy

The ACTG A5360 trial demonstrated that HCV treatment without planned on-treatment monitoring is safe and effective. A study, published in Hepatology Communications, reported the health economic outcomes of MINMON.

Methods

A5360 was a 5-country, single-arm trial providing sofosbuvir/velpatasvir to people with HCV infection with no planned clinic visits between treatment initiation and week 24 sustained virologic response (SVR) evaluation. Trial records included planned/and most unplanned lab tests and visits. Participants completed a 4-week recall questionnaire at weeks 0, 24, 48, and 72 reporting hospital nights, emergency department visits, and ambulatory visits. Researchers tabulated consumption and multiplied units of consumption by country-specific cost. They report the cost and cost per SVR of MINMON (2020 US$) from program and health sector perspectives. Sensitivity analyses compared MINMON costs to the standard of care (SoC). Researchers consulted in-country experts to develop country-specific SoC treatment protocols and used micro-costing to estimate their costs. They compare the cost/SVR in MINMON with that of the simulated SoC, varying the expected SVR with the SoC.

Results

MINMON cost/SVR (program perspective) varied by country from $1692/SVR (Thailand) to $27,632/SVR (United States). The cost/SVR (health sector perspective) ranged from $6273/SVR (South Africa) to $123,974/SVR (United States). MINMON had a lower cost/SVR than SoC across broad assumptions about SVR proportions, especially in low- and middle-income countries. In the United States, MINMON had an appealing cost per cure compared to the SoC, unless retention on treatment fell below the SoC.

Conclusions

MINMON is a cost-saving strategy for HCV treatment, particularly in low- and middle-income country settings.

Access full study results here.